Homing in on Clinical Advances in Hematologic Malignancies in Chicago

We recently traveled to Chicago, Illinois for a State of the Science Summit™ on Hematologic Malignancies. At the meeting, faculty from Rush University Medical Center shed light on ongoing research that is poised to add new options to the armamentarium in myelofibrosis, highlighted the novel agents that have strengthened treatment options in non-Hodgkin lymphoma, and discussed treatment considerations for patients with Hodgkin lymphoma. Moreover, faculty shared insights on the novels agents and combinations that have transformed the multiple myeloma treatment paradigm and provided perspective on ongoing research with blinatumomab and CAR T-cell therapy in new settings in acute lymphoblastic leukemia.